USFDA issues EIR for Aurobindo Pharma arm AP facility
Hyderabad: Aurobindo Pharma has announced that the U.S. Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Unit IV of APL Healthcare Limited, a wholly-owned subsidiary of the Company, situated in Andhra Pradesh, classifying it as 'voluntary action indicated' (VAI).
VAI means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
USFDA had inspected the said facility from September 13 to September 19, 2023 and issued a ‘Form 483’ with 1 observation at the end of the inspection.
Read also: USFDA issues 1 observation for Aurobindo Pharma arm AP facility
"The U.S. Food and Drug Administration (FDA) had conducted an inspection at the Unit IV, a Formulation manufacturing facility, of APL Healthcare Limited, a wholly owned subsidiary of the Company, situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from September 13 to September 19, 2023," Aurobindo stated in a recent BSE filing.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.